@article{ref1,
title="Neuropsychiatric symptoms and alzheimer's disease biomarkers predict driving decline: brief report",
journal="Journal of Alzheimer's disease",
year="2017",
author="Babulal, Ganesh M. and Stout, Sarah H. and Head, Denise and Holtzman, David M. and Fagan, Anne M. and Morris, John C. and Roe, Catherine M.",
volume="58",
number="3",
pages="675-680",
abstract="We examined whether neuropsychiatric symptoms (NPS) interact with cerebrospinal fluid (CSF) biomarkers (amyloid-β42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, and ptau181/Aβ42) of Alzheimer's disease pathology to predict driving decline among cognitively-normal older adults (N = 116) aged ≥65. Cox proportional hazards models examined time to receiving a rating of marginal or fail on the driving test. Age, education, and gender were adjusted in the models. Participants with more abnormal CSF (Aβ42, tau/Aβ42, ptau181/Aβ42) and NPS were faster to receive a marginal/fail on the road test compared to those without NPS. NPS interact with abnormal CSF biomarkers to impact driving performance among cognitively-normal older adults.<p /> <p>Language: en</p>",
language="en",
issn="1387-2877",
doi="10.3233/JAD-170067",
url="http://dx.doi.org/10.3233/JAD-170067"
}